Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (not Galectin Therapeutics Inc.) on April 12, 2002. The report addresses a material restatement of financial results for the fiscal year ended December 31, 2000, and the first three quarters of fiscal year 2001.
Key Financial Metrics and Restatement Impact
The filing details significant adjustments to net loss and loss per share due to accounting corrections. The filing text does not provide data on revenue, cash flow, margins, debt balances, or liquidity positions outside of the loss figures.
| Period | Net Loss (As Previously Reported) | Net Loss (As Restated) | Loss Per Share (As Previously Reported) | Loss Per Share (As Restated) |
|---|---|---|---|---|
| Year Ended Dec 31, 2000 | $(112,927) | $(184,582) | $(0.01) | $(0.01) |
| Three Months Ended Mar 31, 2001 | $(229,511) | $(360,813) | $(0.02) | $(0.03) |
| Six Months Ended Jun 30, 2001 | $(827,654) | $(2,004,011) | $(0.07) | $(0.16) |
| Nine Months Ended Sep 30, 2001 | $(1,513,945) | $(3,193,321) | $(0.12) | $(0.24) |
| Cumulative (Inception to Sep 30, 2001) | $(1,626,872) | $(3,377,903) | N/A | N/A |
Material Changes and Causes
Management identified three primary accounting errors necessitating the restatement:
- Convertible Debt Allocation: Proceeds from convertible debt issued in 2000 and 2001 were incorrectly treated. A majority should have been allocated to equity components (common shares and embedded beneficial conversion features), creating a debt discount to be accreted. When the debt became immediately convertible in June 2001, the remaining discount was expensed.
- Warrant Valuation: Warrants granted in August 2001 as an inducement to convert notes were not previously recorded. Their fair value must be recorded as a debt conversion expense in the third quarter of 2001.
- Expense Timing: Salaries and consulting expenses recorded in 2001 related to services performed in 2000 were reclassified to 2000 as a liability and expense.
Outlook and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the immediate impact of the restatement. The primary contingency is the correction of historical financial data, which significantly increases the reported cumulative net loss.
Investor Verification Checklist
- Verify the corrected financial statements for the fiscal year 2000 and Q1-Q3 2001 in subsequent filings (e.g., 10-K or 10-Q).
- Confirm the total outstanding debt and equity structure following the reclassification of convertible debt proceeds.
- Assess the impact of the increased cumulative net loss on the company's working capital and ability to continue operations.
- Review the valuation methodology used for the embedded beneficial conversion features and warrants.